Advanced Breast Cancer, Metastatic Breast Cancer
Conditions
Sponsors
AstraZeneca
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Genders Eligible for Study: Female Criteria Inclusion Criteria: - Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor - Requiring hormonal treatment - Postmenopausal women defined as a woman who has stopped having menstrual periods Exclusion Criteria: - Treatment with more than one previous regimen of systemic anticancer therapy other than endocrine therapy for advanced breast cancer - Treatment with more than one previous regimen of endocrine therapy for advanced breast cancer - An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy Primary Outcomes: The objective response rate will be analysed when all patients have been in the study for 6 months. Secondary Outcomes: Pharmacokinetics, time to progression, duration of response, clinical benefit rate and tolerability will be analyzed when all patients have been in the study for 6 months. | — |
Outcome results
None listed